RadNet, Inc.
No SEC Form 4 filings for $RDNT in the last 30 days.
RadNet (NASDAQ: RDNT) will report earnings tomorrow after market close. The company previously beat revenue expectations with $575.6 million in revenue, up 22.1% year over year, but missed EPS estimates. For the upcoming quarter, analysts expect revenue growth of 22.1% YoY. The article cites an average analyst price target of $89.75 versus a $71.57 share price.
DeepHealth, a RadNet subsidiary (NASDAQ: RDNT), said it received two FDA 510(k) clearances for its Breast Suite: Breast Arterial Calcification (BAC) Assessment and prior-exam integration into ProFound Pro, to be marketed as Mammo Dx. Both are now commercially available in the U.S. DeepHealth reported BAC performance of >90% sensitivity and >88% specificity.
SWARTZ DAVID L sold 2,699 shares of RadNet, Inc. (RDNT) at $53.89 ($0.15M total) on 2026-06-18.
Over the past 7 days, alphai's AI scored 1 news story mentioning RDNT (RadNet, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent RDNT coverage spans insider activity, financial news and earnings.
Earnings timing and consensus expectations are the actionable inputs, but the article does not add new guidance beyond what the market already expects.
FDA clearances expand DeepHealth’s breast AI product suite and enable deployment across RadNet imaging centers, potentially supporting incremental utilization and revenue.
Routine insider open-market sale disclosed via SEC Form 4; it signals liquidity/position management rather than a new fundamental catalyst.
Routine insider open-market sale by the CEO; typically low signal versus buys, but can slightly affect sentiment/positioning.
Insider selling is a modest negative signal, but this is not a 10b5-1 plan and is unlikely to be a standalone fundamental catalyst.
alphai scores every news story that mentions RDNT with an AI model for sentiment and relevance, and aggregates insider trades from RadNet, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
RadNet (NASDAQ: RDNT) will report earnings tomorrow after market close. The company previously beat revenue expectations with $575.6 million in revenue, up 22.1% year over year, but missed EPS estimates. For the upcoming quarter, analysts expect revenue growth of 22.1% YoY. The article cites an average analyst price target of $89.75 versus a $71.57 share price.
4 min readDeepHealth, a RadNet subsidiary (NASDAQ: RDNT), said it received two FDA 510(k) clearances for its Breast Suite: Breast Arterial Calcification (BAC) Assessment and prior-exam integration into ProFound Pro, to be marketed as Mammo Dx. Both are now commercially available in the U.S. DeepHealth reported BAC performance of >90% sensitivity and >88% specificity.
5 min readSWARTZ DAVID L sold 2,699 shares of RadNet, Inc. (RDNT) at $53.89 ($0.15M total) on 2026-06-18.
2 min readWesdorp Cornelis (Pres & CEO, Digital Health) sold 4,750 shares of RadNet, Inc. (RDNT) at $58.11 ($0.28M total) on 2026-06-16.
2 min readForthuber Stephen M (Pres & CEO-Eastern Operations) sold 44,067 shares of RadNet, Inc. (RDNT) at an average of $58.16 ($57.79–$58.61, $2.56M total) across 2 trades on 2026-06-15.
2 min readRadNet, Inc. (RDNT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 radnet_ex1001.htm INCREMENTAL AMENDMENT NO. 3 TO CREDIT AND GUARANTY AGREEMENT Exhibit 10.1 INCREMENTAL AMENDMENT NO. 3 TO CREDIT AND GUARANTY AGREEMENT INCREMENTAL AMENDMENT NO. 3 TO CREDIT AND GUARANTY AGREEMENT, dated as of June 10, 2026 (this “ Amendment ”), to the
4 min readBarclays analyst Andrew Mok cut RadNet’s (RDNT) price target to $65 from $70 while keeping an Overweight rating, citing continued outperformance in advanced volume growth and pricing in its imaging business. The article notes RadNet’s April plan to acquire a majority stake in Intermountain Medical Imaging via a joint venture with Saint Alphonsus Health System.
4 min readRadNet, Inc. has formed a joint venture with Trinity Health’s Saint Alphonsus Health System by acquiring a majority stake in Intermountain Medical Imaging, which operates five outpatient imaging centers in Boise, Idaho. This collaboration will integrate RadNet's DeepHealth solutions, including AI-powered tools for clinical interpretation, reporting, and operational efficiencies, across the five locations. The partnership aims to enhance diagnostic imaging services, improve patient care, and streamline operations, projecting approximately $30 million in annual revenue for RadNet.
4 min readRadNet Inc (RDNT) shares fell 3.5% to $55.89, leading to a 21.7% year-to-date decline, yet GuruFocus identifies the stock as modestly undervalued with a GF Value™ of $64.75 and assigns a strong GF Score™ of 84/100. Despite its attractive valuation and promising growth potential, the company exhibits lower financial strength and significant insider selling, which suggests caution for investors. RadNet's current forward P/E ratio is also notably lower than its historical median, further supporting the undervaluation claim.
4 min readRadNet, Inc. (NASDAQ: RDNT) announced it will host a conference call on Monday, May 11, 2026, at 7:30 a.m. Pacific Time to discuss its first quarter 2026 financial results. Investors can listen by dialing specified numbers or via webcast. The company is a national leader in diagnostic imaging services and digital health solutions.
2 min read
